Synonym
CHF 2819; CHF2819; CHF-2819; Ganstigmine hydrochloride; Ganstigmine HCl.
IUPAC/Chemical Name
Carbamic acid, (2-ethylphenyl)-, (1R,3aS,8aS)-1,2,3,3a,8,8a-hexahydro-1,3a-dimethyl-1-oxidopyrrolo(2,3-b)indol-5-yl ester, monohydrochloride
InChi Key
CVDHRWXJJRBPFA-IEGNKYQISA-N
InChi Code
InChI=1S/C21H25N3O3.ClH/c1-4-14-7-5-6-8-17(14)23-20(25)27-15-9-10-18-16(13-15)21(2)11-12-24(3,26)19(21)22-18;/h5-10,13,19,22H,4,11-12H2,1-3H3,(H,23,25);1H/t19-,21-,24?;/m0./s1
SMILES Code
Cl.CCc1ccccc1NC(=O)Oc2ccc3N[C@@H]4[C@@](C)(CCN4(=O)C)c3c2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
403.90
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Trabace L, Cassano T, Steardo L, Pietra C, Villetti G, Kendrick KM, Cuomo V. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther. 2000 Jul;294(1):187-94. PubMed PMID: 10871311.
2: Bartolucci C, Siotto M, Ghidini E, Amari G, Bolzoni PT, Racchi M, Villetti G, Delcanale M, Lamba D. Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819). J Med Chem. 2006 Aug 24;49(17):5051-8. PubMed PMID: 16913695.
3: Jhee SS, Fabbri L, Piccinno A, Monici P, Moran S, Zarotsky V, Tan EY, Frackiewicz EJ, Shiovitz T. First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease. Clin Neuropharmacol. 2003 May-Jun;26(3):164-9. PubMed PMID: 12782920.
4: Trabace L, Cassano T, Loverre A, Steardo L, Cuomo V. CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor. CNS Drug Rev. 2002 Spring;8(1):53-69. Review. PubMed PMID: 12070526.
5: Trabace L, Cassano T, Cagiano R, Tattoli M, Pietra C, Steardo L, Kendrick KM, Cuomo V. Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels. Brain Res. 2001 Aug 10;910(1-2):182-6. PubMed PMID: 11489269.
